Products - Blood conditions | Topic

Showing 13 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 January 2025
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Suspected sepsis: recognition, diagnosis and early management
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 August 2025
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 August 2025
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood conditions Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 13 products

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266

Suspected sepsis: recognition, diagnosis and early management

Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

Exagamglogene autotemcel for treating sickle cell disease [ID4016]

Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284

Blood conditions Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 13 products

Status
1 selected